scholarly journals Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data

2019 ◽  
Vol 8 (2) ◽  
pp. 285-299
Author(s):  
Kiyotaka Yamazaki ◽  
Dendy Macaulay ◽  
Yan Song ◽  
Yuri Sanchez Gonzalez
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Economic Burden ◽  
Claims Data ◽  
Antiviral Treatment ◽  
Observational Cohort Study ◽  
Observational Cohort

scholarly journals Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study

2022 ◽  
Vol 13 ◽  
pp. 204062232110676
Author(s):  
Ming-Han Hsieh ◽  
Tzu-Yu Kao ◽  
Ting-Hui Hsieh ◽  
Chun-Chi Kao ◽  
Cheng-Yuan Peng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Observational Cohort Study ◽  
Histological Changes ◽  
Entire Cohort ◽  
Fibrosis Progression ◽  
Observational Cohort

Background: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. Methods: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). Results: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) ( n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases ( n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort ( n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases ( n = 59) was significantly higher than that in non-SVR cases ( n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. Conclusions: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.

scholarly journals Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

The Lancet ◽  
2019 ◽  
Vol 393 (10179) ◽  
pp. 1453-1464 ◽  
Author(s):  
Fabrice Carrat ◽  
Hélène Fontaine ◽  
Céline Dorival ◽  
Mélanie Simony ◽  
Alpha Diallo ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Clinical Outcomes ◽  
Chronic Hepatitis C ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Genetic polymorphisms as the predictors of response to antiviral treatment in chronic hepatitis C virus infection

2011 ◽  
Vol 152 (22) ◽  
pp. 876-881
Author(s):  
Alajos Pár
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Genetic Polymorphisms ◽  
Chronic Hepatitis C ◽  
Genome Wide Association Study ◽  
Antiviral Treatment ◽  
Hcv Infection ◽  
Snp Analysis ◽  
Chronic Hcv

The review discusses the genetic polymorphisms involved in the pathogenesis of hepatitis C virus (HCV) infection, that may determine the outcome of disease. In this field earlier both certain major histocompatibility complex (MHC) alleles and some cytokine gene variants have also been studied. Recently, the genome-wide association study (GWAS) and targeted single nucleotide polymorphism (SNP) analysis have revealed that a variant in the promoter region of interleukin-28B (IL-28B) gene is strongly linked to viral clearance and it may be the strongest pretreatment predictor of treatment response in chronic hepatitis C. Last year it was shown that two genetic variants leading to inosine triphosphatase deficiency protect against haemolytic anemia in patients receiving ribavirin during antiviral treatment for chronic HCV infection. Orv. Hetil., 2011, 152, 876–881.

The Effects of Interferon and Ribavirin in Chronic Hepatite C

2017 ◽  
Vol 68 (9) ◽  
pp. 2147-2150
Author(s):  
Liliana Coldea ◽  
Florin Grosu ◽  
Alina Liliana Pintea ◽  
Sebastian Ioan Cernusca Mitariu ◽  
Nicolae Grigore ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Public Health Problem ◽  
Complete Response ◽  
Extrahepatic Manifestations ◽  
Hépatite C ◽  
Response Versus

The chronic hepatitis C is a frequently problem in worldwide, the number of infected individuals is high and go on, getting a public health problem [1]. In Romania there are nearly 1 million persons infected with hepatitis C virus, the scope of spreading is related with specific risk factors. An important number of infection with hepatitis C virus present simultaneous extrahepatic manifestations proved to be alone manifestation tracing; its important for diagnosis and treatment. We analyzed the effects of interferon and ribavirin in chronic hepatitis C in General C.F. Hospital Sibiu, between 2008 � 2012. The association between infection with hepatitis C virus and extrahepatic manifestations is important to be recognized for adequate diagnosis tests. By comparing the results of therapy in patients with hepatic and extrahepatic manifestations, the study found that 30 patients (58.83 %) with liver manifestations had an incomplete response versus 10 patients (26.32 %) with extrahepatic manifestations; 11 patients (21.54 %) with hepatic manifestations had a complete response versus 3 patients (7.89 %) with extrahepatic manifestations; and 10 patients (19.63 %) with hepatic manifestations did not respond to treatment versus 25 patients (65.79 %) with extrahepatic manifestations. Analyzing the results of antiviral therapy in patients with hepatic manifestations and those with extrahepatic manifestations, antiviral treatment appears to be more advantageous in cases with only hepatic manifestations.

Sign in / Sign up

Export Citation Format

Share Document